TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00697346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib (MLN8237) PIC or ECT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib (MLN8237) PIC or ECT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib (MLN8237) PIC or ECT
Study: NCT01020071

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pattern scanning laser iridotomy and iridoplasty
Description: peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
Study: NCT00419562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: 7.5 mg oral insulin or placebo given before breakfast on a daily basis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule designed to match active drug
Study: NCT03331952

Intervention type: OTHER
Intervention: Prospective study
Description: To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
Study: NCT01015248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab and Bendamustine
Description: Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
Study: NCT03331952

Intervention type: OTHER
Intervention: Prospective study
Description: To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015

Intervention type: OTHER
Intervention: Cross-sectional surveys
Description: Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
Study: NCT00564382

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac magnetic Resonance study
Description: Routine cardiac MR study including contrast application
Study: NCT03317691

Intervention type: DIAGNOSTIC_TEST
Intervention: electrocardiogram diagnosed by artificial intelligence
Description: According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
Study: NCT00870415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT02736734

Intervention type: DRUG
Group type: OTHER
Intervention: CRH
Description: CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
Study: NCT02515175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline
Study: NCT02344212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESENCIAL Para Vivir: a weight loss program for Latinas
Description: Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
Study: NCT02288234

Intervention type: DRUG
Intervention: Vibativ
Description: This is an observational study for patients who were already prescribed Vibativ.
Study: NCT05443776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomaterial implantation
Description: Implant a approved biomaterial by European Regulatory Agencies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomaterial implantation
Description: Implant a approved biomaterial by European Regulatory Agencies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomaterial implantation
Description: Implant a approved biomaterial by European Regulatory Agencies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomaterial implantation
Description: Implant a approved biomaterial by European Regulatory Agencies
Study: NCT03241992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyChart Disease Specific
Description: Subjects receive targeted IBD information and reminders as well as mood questionnaires.
Study: NCT02937311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES
Description: Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Physiotherapy
Description: All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Physiotherapy
Description: All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Physiotherapy
Description: All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
Study: NCT05443776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomaterial implantation
Description: Implant a approved biomaterial by European Regulatory Agencies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomaterial implantation
Description: Implant a approved biomaterial by European Regulatory Agencies
Study: NCT00701012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preservation of nerve fibers around IMA
Description: low ligation
Study: NCT03819361

Intervention type: DIAGNOSTIC_TEST
Intervention: pulse-oximetry
Description: Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
Study: NCT04458909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00413218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Administered by intravenous infusion.
Study: NCT00701012

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection of nerve fibers around IMA
Description: high ligation
Study: NCT02092207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL7016 900mg
Description: oral administration, 150mg 3tab, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL7016 600mg
Description: oral administration, 150mg 3tab, bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration, 150mg 3tab, bid
Study: NCT03325569

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: oral glucose tolerance test
Description: GLP1 response to oral glucose load during oral glucose tolerance test was assessed.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: oral glucose tolerance test
Description: GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
Study: NCT04555460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemicraniectomy
Description: Large hemicraniectomy and duraplasty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative medical therapy
Description: Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
Study: NCT02698826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol for rapid FiO2 optimization
Description: We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas \[ABG\] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value \<100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction.
Study: NCT02526602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preservation (endopelvic fascia)
Description: Robotic assisted radical prostatectomy with preserving of endopelvic fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opening (endopelvic fascia)
Description: Robotic assisted radical prostatectomy with opening of endopelvic fascia
Study: NCT00941408

Intervention type: PROCEDURE
Intervention: Diagnostic tumor core biopsy
Study: NCT02289313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Youth Living Program
Description: Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
Study: NCT02333357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia 12-Step Toolkit
Description: The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
Study: NCT03273335

Intervention type: DEVICE
Intervention: Millipore biomarker assay plate
Description: Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
Study: NCT03986203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spry Belt
Description: The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spry Belt
Description: The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
Study: NCT02397304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
Study: NCT01479868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
Study: NCT02486016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic reference fentanyl TDS
Description: 25 µg/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apotex generic fentanyl TDS
Description: 25 µg/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mylan generic fentanyl TDS
Description: 25 µg/hour
Study: NCT01177007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere, Yttrium-90 glass Microspheres
Description: Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
Study: NCT04485897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: icare HOME device (Icare Oy, Vanda, Finland)
Description: icare HOME device versus hospital based measurements
Study: NCT02678351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Undergo 68Ga-PSMA-11 PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Undergo 68Ga-PSMA-11 PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo 68Ga-PSMA-11 PET/MRI
Study: NCT00904735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study: NCT01988714

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: (TCT) plus evidence-based SE
Description: Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (CG) plus evidence-based SE
Description: (CG) plus evidence-based SE
Study: NCT01919229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011 (ribociclib)
Description: Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011 (ribociclib)
Description: Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole was supplied in 2.5mg tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole was supplied in 2.5mg tablets for oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: Letrozole was supplied in 2.5mg tablets for oral use.
Study: NCT01632020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
Study: NCT01511562

Intervention type: DRUG
Group type: OTHER
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: cytarabine
Description: Given IV
Study: NCT01632020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
Study: NCT00962637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 12.5 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: 25 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel
Description: 5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study: NCT01749969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Pharmaceutical form:capsules Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
Study: NCT01035671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-tocopherolquinone (A0001)
Description: 28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-tocopherolquinone (A0001)
Description: 28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 28 days of placebo oral capsules. Treatment taken twice daily with meals.
Study: NCT01680666

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: central line placement
Description: central line placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: central line placement
Description: central line placement
Study: NCT01511562

Intervention type: DRUG
Group type: OTHER
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: thiotepa
Description: Given IV
Study: NCT01680666

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided central venous access
Study: NCT02738749

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
Study: NCT03097965

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROGRAM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Study: NCT03101904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo